Skip to main content
S&P 5007,696.02+1.68%DOW53,421.58+3.16%NASDAQ25,762.53+1.54%BTC$80,148.00+3.09%ETH$2,418.41+5.72%GOLD$4,077.00+3.47%OIL$88.57-7.83%
Smart Investors Daily
SID Premium
VR

NASDAQ · VRDN

Viridian Therapeutics, Inc.

Healthcare · Biotechnology

$25.15

Up+$3.39 (+13.48%)

Updated Nov 4, 2026, 8:38 PM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.64B
P/E ratio
-7.73
Dividend yield
0.00%
52-week range
$13.18 – $30.42
Volume
4.07M
Avg. volume
1.41M

Price performance · VRDN

VRDN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

VRDN closed at $25.15 after 21 trading sessions, up 38.04% for the selected period.

Last close
$25.15
Period change
+38.04%
Period low
$18.22
Period high
$25.30
Daily close
View OHLC price history
VRDN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$25.605$26.21$24.52$25.154.07M
Nov 2, 2026$24.45$25.575$23.97$25.303.39M
Oct 30, 2026$24.77$25.00$24.14$24.671.71M
Oct 29, 2026$24.35$25.32$24.23$24.801.91M
Oct 28, 2026$23.72$24.42$23.66$24.271.41M
Oct 27, 2026$23.29$24.115$23.19$24.092.81M
Oct 26, 2026$22.50$23.35$22.33$23.341.52M
Oct 23, 2026$22.75$22.75$21.92$22.371.18M
Oct 22, 2026$23.00$23.59$22.66$22.821.55M
Oct 21, 2026$22.50$23.29$22.465$23.011.92M
Oct 20, 2026$21.10$22.68$20.85$22.431.97M
Oct 19, 2026$19.23$20.875$19.07$20.802.58M
Oct 16, 2026$19.67$19.78$18.94$19.032.46M
Oct 15, 2026$18.69$19.78$18.535$19.562.17M
Oct 14, 2026$18.19$18.745$18.01$18.383.73M
Oct 13, 2026$18.04$18.33$17.96$18.222.12M
Oct 12, 2026$19.00$19.185$18.21$18.301.95M
Oct 9, 2026$18.31$18.72$18.16$18.661.33M
Oct 8, 2026$18.02$18.44$17.59$18.342.44M
Oct 7, 2026$18.02$18.73$17.915$18.281.69M
Oct 6, 2026$19.00$19.13$18.07$18.222.2M

Latest VRDN news

The latest Smart Investors Daily articles mentioning VRDN.

Stock researchCompany · Overview

VRDN research

Overview

Company profile and research snapshot.

Company profile

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$41.57
Implied upside
—
Analysts
—
VRDN recent ratings
DateFirmRatingTarget
Sep 22, 2026RBC CapitalOutperform—
Aug 7, 2026RBC CapitalOutperform—
Aug 7, 2026Truist SecuritiesBuy—
Jun 30, 2026WedbushOutperform—
Jun 30, 2026Truist SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

How FDA Approval Will Impact Viridian Therapeutics Stock

Viridian Therapeutics received FDA approval in June 2026 for Lumvoa, an IGF-1R antibody for active and chronic Thyroid Eye Disease, following Phase III data showing meaningful clinical benefits with a 12-week, 5-infusion IV regimen. The approval gives Viridian Therapeutics its first commercial product in a roughly US$2b Thyroid Eye Disease IGF-1R market that currently treats an estimated 6,000 to 7,000 patients each year with single digit class penetration. We will now look at how the...

Yahoo · Oct 20, 2026

Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026

WALTHAM, Mass., October 20, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that it will report third quarter 2026 financial results before the market opens on Wednesday, November 4, 2026.

Yahoo · Oct 17, 2026

Viridian Therapeutics (VRDN) Stock May Look Stretched Against Its Sales Base

Viridian Therapeutics has seen a mixed share price story in recent years, which raises a straightforward question for anyone looking at the stock today. Is the current US$19.03 price tag adequately grounded in what the company is generating through its sales? Over the past 3 years the stock has gained 64.3%, which puts real weight on whether the underlying sales base can carry that kind of share price performance. The business model and execution track record matter here because any shift in...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By